Novo Nordisk A/S (Novo Nordisk A/S) EBIT per Share : $3.42 (TTM As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S EBIT per Share?

Novo Nordisk A/S's EBIT per Share for the three months ended in Dec. 2023 was $0.83. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.42.

During the past 12 months, the average EBIT per Share Growth Rate of Novo Nordisk A/S was 38.60% per year. During the past 3 years, the average EBIT per Share Growth Rate was 25.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was 17.20% per year. During the past 10 years, the average EBIT per Share Growth Rate was 11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Novo Nordisk A/S's EBIT per Share or its related term are showing as below:

NVO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -50.6 Med: 14.3 Max: 199.6
Current: 25.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Novo Nordisk A/S was 199.60% per year. The lowest was -50.60% per year. And the median was 14.30% per year.

NVO's 3-Year EBIT Growth Rate is ranked better than
76.95% of 1306 companies
in the Biotechnology industry
Industry Median: 3.5 vs NVO: 25.40

Novo Nordisk A/S's EBIT for the three months ended in Dec. 2023 was $3,734 Mil.

Novo Nordisk A/S EBIT per Share Historical Data

The historical data trend for Novo Nordisk A/S's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S EBIT per Share Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

1.53

1.87

1.96

2.18

3.43

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.26	0.82	0.79	0.96	0.83

Novo Nordisk A/S EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Novo Nordisk A/S's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	15394.159	/	4494.800
=	3.42

Novo Nordisk A/S's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	3733.686	/	4474.400
=	0.83

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.42

Novo Nordisk A/S (NYSE:NVO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Novo Nordisk A/S EBIT per Share Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.